Startup Ideas Bank
Automating a critical, high-friction healthcare process with a proven B2B SaaS model.
AI roast score: 88/100 (A-)
The idea
This isn't just another SaaS pitch; it's a surgical strike at hospital admin hell. Pre-auth for radiology/oncology? They're taking a scalpel to a gaping wound. $9.1M ARR and Series A closed? They've already proven the patient can pay for the cure.
In the founder's own words
We're building a clinical workflow platform that helps US hospital networks automate insurance pre-authorization for radiology and oncology orders. We sell to enterprise hospital systems on annual subscriptions averaging $24k per facility, currently profitable with 380 hospitals across 14 states and $9.1M ARR. We just closed an $18M Series A and are expanding into Canada and the UK next year. Main worry is whether we can keep our HIPAA + state-by-state compliance posture as we scale internation
The roast
Alright, let's cut the fluff. You're building a glorified EDI translator for the Byzantine world of US healthcare pre-authorizations. "Automating insurance pre-authorization for radiology and oncology orders" – sounds exciting, right? It's not. It's the digital equivalent of unjamming a copier, but with more regulatory risk and less pizza. You've managed to find a massive pain point that hospitals have been bleeding money and time on for decades. Congratulations, you've bottled lightning in a regulatory minefield. The $9.1M ARR and $18M Series A are nice validation, but let's be clear: this is a grind, not a rocket ship. Your biggest worry isn't HIPAA compliance, it's whether you can replicate this beast of a workflow engine across different countries with their own flavor of bureaucratic insanity. Good luck with that.
Red flags
- International compliance complexity (HIPAA vs. GDPR/other) is a monumental task and a capital drain.
- Enterprise sales cycles are notoriously long and costly, even with proven ARR.
- The core value proposition is process automation, which can be commoditized or disrupted by payer-side solutions.
Verdict
Continue executing on your established US market while meticulously de-risking international expansion with pilot programs and deep regulatory partnerships.